RESUMEN
The ovariectomized rat is the most commonly used animal model of human postmenopausal osteoporosis, exhibiting a high rate of bone turnover with resorption exceeding formation. At present, bone turnover is quantified directly by dynamic histomorphometry. The aim of the present study was to determine whether the measurement of the urinary output of some specific bone collagen catabolites--pyridinolines and hydroxylysine glycosides--could be used to indirectly monitor the initial phase of bone turnover increase in ovariectomized 90-day-old rats. Ninety-day-old female rats were randomly divided into three groups (n = 6): ovariectomized, sham-operated and non-treated controls. Urine samples (24 h) were collected 6 days before surgery and twice weekly for the 4 weeks following ovariectomy. Urinary excretion of pyridinoline (PYD), deoxypyridinoline (DPD), glucosyl-galactosyl-hydroxylysine (GGHYL) and galactosyl-hydroxylysine (GHYL) were measured. As expected, ovariectomy was associated with a significant decrease in bone mineral density in both the proximal tibial and distal femoral metaphysis. Compared with both sham-operated and control animals, ovariectomized rats showed significant increases in PYD, GGHYL, and GHYL urinary output 8 days after surgery and in DPD output after 15 days. These changes were maintained throughout the study. The results confirm that measurement of the urinary excretion of pyridinolines and hydroxylysine glycosides represents a powerful tool for detecting the onset of bone turnover in ovariectomized 90-day-old rats.
Asunto(s)
Huesos/metabolismo , Glicósidos/orina , Ovariectomía , Aminoácidos/orina , Animales , Femenino , Hidroxilisina/análogos & derivados , Hidroxilisina/orina , Ratas , Ratas Sprague-Dawley , Factores de TiempoRESUMEN
In an attempt to change the beta-adrenergic properties of completely aliphatic 3-(methyleneaminoxy)propanolamine derivatives, from antagonist to agonist, while still retaining the beta 2-selectivity, we described, in a previous paper, the synthesis of a series of such derivatives possessing a hydroxy or methoxy group linked to the aliphatic substituent present on the oximic carbon. However, pharmacological tests indicated that these compounds maintain the competitive antagonism on beta receptors. In this paper, the synthesis and the results of functional tests on isolated preparations are reported for a new series of 3-(substituted-benzylideneaminoxy)propanolamine derivatives in which either the hydroxy or the methoxy group is linked to a phenyl ring present on the oximic carbon. The results obtained are then discussed, taking into account the conformational and reactivity properties of these compounds, determined by means of theoretical calculations.
Asunto(s)
Agonistas Adrenérgicos beta/síntesis química , Compuestos de Bencilideno/síntesis química , Propanolaminas/síntesis química , Agonistas de Receptores Adrenérgicos beta 1 , Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacología , Animales , Compuestos de Bencilideno/farmacología , Cobayas , Técnicas In Vitro , Masculino , Conformación Molecular , Contracción Muscular/efectos de los fármacos , Propanolaminas/farmacología , Espectrofotometría Infrarroja , Relación Estructura-Actividad , Tráquea/efectos de los fármacosRESUMEN
The N-isopropyl- and N-t-butyl-substituted 1-[o-(3-amino-2-hydroxypropoxy)benzylideneaminoxy]-3-amino-2-propa nols (7a,b) and their meta (8a,b) and para (9a,b) isomers, in which a single aromatic ring is substituted both by the oxypropanolaminic chain of (aryloxy)propanolaminic beta-adrenergic antagonists (AOPAs) and the [(methyleneamino)oxy]propanolaminic chain of [(methyleneamino)oxy]-propanolaminic beta-blocking drugs (MAOPAs), were synthesized and assayed for their beta-adrenergic activity by functional tests on isolated preparations. Compounds 7-9 represent a new type of molecular duplication of beta-adrenergic drugs, formally deriving from the sharing of the aromatic portions of two different pharmacophoric subunits, namely the (aryloxy)propanolaminic portion of AOPAs and the [(benzylideneamino)oxy]propanolaminic portion of aryl-substituted MAOPAs. The pharmacological results showed that the beta-blocking activity of compounds 7-9 is closely related to the way in which the two subunits are linked by the aromatic nucleus: the activity decreases on passing from the ortho-compounds (7a,b) to the meta (8a,b) and then to the para (9a,b) isomers. A comparison of this activity trend with those found for series of both beta-blocking AOPAs and aryl-substituted MAOPAs seems to indicate that compounds 7-9 can be considered more as AOPAs substituted on the phenyl ring by a [(methyleneamino)oxy]propanolaminic chain rather than as aromatic MAOPAs substituted on the same phenyl moiety by an oxypropanolaminic portion.
Asunto(s)
Antagonistas Adrenérgicos beta/síntesis química , Propanolaminas/química , Antagonistas Adrenérgicos beta/farmacología , Animales , Cobayas , Atrios Cardíacos , Masculino , Conformación Molecular , Contracción Miocárdica/efectos de los fármacos , Propanolaminas/farmacología , TráqueaRESUMEN
The activity of a novel calcitonin SB 205614 was compared with salmon calcitonin (sCT) and (Asu1,7)-eel calcitonin (ELC) in six different models of osteoclastic bone resorption in vitro and in vivo. SB 205614 is an ELC analogue that has an acetylenic bridge instead of the natural disulphide bridge, rendering the molecule more stable biologically than sCT and equally stable to ELC. Our aim was to determine whether this structural change compromised biologic activity, and if not, whether the increased stability could be used to exploit novel modes of administration. In the in vitro assays of pit formation by disaggregated rat osteoclasts on cortical bone slices (DROcA) and PTH stimulation of 45Ca-release from prelabeled fetal rat bone, no significant differences in activity were observed between the three calcitonins. In the DROcA, IC50s of 0.003, 0.015 and 0.064 pg/ml for sCT, ELC, and SB 205614, respectively, were determined, with total or near complete inhibition observed at 1 pg/ml (0.3 pM). In the assay of PTH-stimulation of 45Ca release, IC50s were measured of 5.5, 4.8, and 12.9 pM for sCT, ELC, and SB 205614, respectively; in every case maximal inhibition (ca. 80%) was observed at 30 and 100 pM. The internationally approved U.S. Pharmacopoeia bioassay of hypocalcemia in the rat following intravenous (IV) administration indicated that SB 205614 had a greater potency than ELC or sCT. More important, a full dose-hypocalcemic response curve demonstrated significantly increased potency compared to sCT or ELC, as the doses causing 15% lowering of serum calcium (approximately 50% of the maximum effect) were 33.9, 25.2, and 12.9 mg/kg for sCT, ELC, and SB 205614, respectively. As a preliminary means of investigating alternative delivery forms of calcitonin, the time course of the hypocalcemic effect was investigated in the rat and rabbit following IV administration, and was compared with that following intranasal (IN) administration (rat and rabbit), and following intracolonic administration (rat only). Maximal effects were similar, whereas in general the hypocalcemic effect of SB 205614 was of a longer duration than the other two calcitonins; this was reflected in a larger area over the curve (AOC). However, following IN administration in the rabbit, where an aerosol delivery device similar to that used in the clinic was used to administer the calcitonins, SB 205614 (100 IU/kg) induced a highly significant two-fold increase in the AOC compared to ELC or sCT. The calcitonins were also compared in assays designed to measure therapeutic efficacy in the rat.(ABSTRACT TRUNCATED AT 400 WORDS)
Asunto(s)
Resorción Ósea/tratamiento farmacológico , Calcitonina/análogos & derivados , Calcitonina/farmacología , Osteoclastos/efectos de los fármacos , Secuencia de Aminoácidos , Animales , Resorción Ósea/patología , Modelos Animales de Enfermedad , Vías de Administración de Medicamentos , Estudios de Evaluación como Asunto , Hipocalcemia/tratamiento farmacológico , Técnicas In Vitro , Masculino , Datos de Secuencia Molecular , Osteoporosis/tratamiento farmacológico , Conejos , Ratas , Ratas Sprague-Dawley , Ratas WistarRESUMEN
In a previous paper, it had been found that completely aliphatic 3-(methylene aminoxy)propanolamine derivatives showed a good beta-blocking adrenergic activity directed prevalently towards beta 2-tracheal receptors. In an attempt to change the beta-adrenergic properties of these compounds from antagonist to agonist, while still retaining the beta 2-selectivity, a series of new completely aliphatic 3-(methyleneaminoxy)propanolamine derivatives were designed in which either a hydroxylic or a methoxylic group was present on the aliphatic portion linked to the oximic carbon. The synthesis of the new compounds and their beta-adrenergic activity, evaluated by means of functional tests on isolated preparations, are described and discussed; the results obtained are then rationalised on the basis of their conformational and reactivity characteristics, determined by means of theoretical methods.
Asunto(s)
Agonistas Adrenérgicos beta/síntesis química , Propanolaminas/síntesis química , Adrenérgicos , Agonistas Adrenérgicos beta/química , Agonistas Adrenérgicos beta/farmacología , Antagonistas Adrenérgicos beta/síntesis química , Antagonistas Adrenérgicos beta/química , Antagonistas Adrenérgicos beta/farmacología , Animales , Cobayas , Técnicas In Vitro , Conformación Molecular , Músculo Liso/efectos de los fármacos , Propanolaminas/química , Propanolaminas/farmacología , Relación Estructura-ActividadRESUMEN
The effect of the antihypertensive vasodilator, cadralazine, on renal function in the conscious dog was compared to that of hydralazine using inulin and para-aminohippurate clearances. Both drugs were administered as intravenous bolus, at the dose of 1 mg/kg. As expected, hydralazine rapidly decreased mean blood pressure (from 110 to 89 mmHg), significantly increased heart rate (from 109 to 190 beats/min), markedly decreased urine volume (from 0.90 to 0.47 ml/min) and sodium excretion (from 101 to 45 microEq/min), and increased potassium excretion (from 28 to 53 microEq/min). Cadralazine displayed a similar activity on blood pressure and on heart rate, but differently from hydralazine, these effects appeared more slowly and were not accompanied by sodium and water retention. Hydralazine, but not cadralazine, caused a quick and transient decrease in glomerular filtration rate (from 55 to 40 ml/min), whereas both compounds increased renal plasma flow and reduced renal vascular resistance, renal extraction of para-aminohippurate and filtration fraction. Moreover, cadralazine increased plasma renin activity to a lesser extent than hydralazine, and this could explain the different effect on water and sodium excretion after acute administration of the two drugs.
Asunto(s)
Antihipertensivos/farmacología , Hidralazina/farmacología , Riñón/efectos de los fármacos , Piridazinas/farmacología , Animales , Análisis de los Gases de la Sangre , Presión Sanguínea/efectos de los fármacos , Perros , Electrólitos/orina , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Pruebas de Función Renal , Radioinmunoensayo , Renina/sangre , Urodinámica/efectos de los fármacosRESUMEN
The synthesis of a new series of 1-alkoxybenzyl-4-(2-pyrimidyl)piperazines 2-methyl or 2,6-dimethyl substituted, related to piribedil, is described. Besides compounds (IV)-(IX a, b), the isomer (XI) of (V) was also prepared. Central dopaminergic and alpha-blocking activities both in vitro and in vivo were determined for all compounds. Derivatives (IV), (VII), (XI) were also studied for peripheral vasodilator and sympatholytic activities.
Asunto(s)
Piperazinas/síntesis química , Antagonistas Adrenérgicos alfa/síntesis química , Animales , Gatos , Fenómenos Químicos , Química , Miembro Posterior/irrigación sanguínea , Técnicas In Vitro , Dosificación Letal Mediana , Masculino , Ratones , Piribedil/análogos & derivados , Piribedil/síntesis química , Piribedil/farmacología , Piribedil/toxicidad , Ratas , Flujo Sanguíneo Regional/efectos de los fármacos , Simpaticolíticos/síntesis química , Vasodilatadores/síntesis químicaRESUMEN
Hemodynamic activity of cadralazine (ethyl-2-[6-(2-hydroxypropyl)-ethylaminol-3-pyridazinyl hydrazine carboxylate), a new, long-acting antihypertensive agent, was evaluated on systemic and regional circulation in conscious dogs. Cadralazine given i.v. (1 mg/kg) caused a sustained fall in total peripheral vascular resistances and mean blood pressure (from 103 to 90 mmHg) and an increase in heart rate (from 97 to 161 beats/min). Heart rate variations paralleled the drop in peripheral resistances. Cadralazine produced a consistent increase in cardiac output, and this effect was related to the increase in heart rate. No significant change in myocardial contractility was observed. Blood flow was increased and vascular resistances decreased in coronary, iliac and mostly in renal vascular beds, whereas the variations in the mesenteric district were not significant. This hemodynamic pattern characterizes cadralazine as a vasodilator. Changes in hemodynamic responses to epinephrine (1 microgram/kg i.v.) after cadralazine treatment were also evaluated. Cadralazine reduced hypertension and bradycardia effects, increased hypotension and tachycardia responses, and caused a further increase in cardiac output and coronary blood flow. These effects of cadralazine are not due to alpha-blocking or to beta-stimulating properties.
Asunto(s)
Antihipertensivos/farmacología , Hemodinámica/efectos de los fármacos , Piridazinas/farmacología , Vasodilatadores/farmacología , Animales , Gasto Cardíaco/efectos de los fármacos , Perros , Epinefrina/farmacología , Flujo Sanguíneo Regional/efectos de los fármacos , Factores de TiempoRESUMEN
Four new esters (1 b-e) involving the phenolic group of isoxsuprine have been prepared. Preliminary pharmacological evaluation showed that the pivaloyl ester (1 e) (LR693) lowers blood pressure values more gradually than isoxsuprine with a longer-lasting effect. This compound was selected for further assessment as a long-acting peripheral vasodilator.
Asunto(s)
Isoxsuprina/análogos & derivados , Animales , Presión Sanguínea/efectos de los fármacos , Femenino , Isoxsuprina/síntesis química , Isoxsuprina/farmacología , Dosificación Letal Mediana , Masculino , Ratones , Norepinefrina/antagonistas & inhibidores , Ratas , Ratas EndogámicasRESUMEN
A few analogs of the isoxsuprine drug with the phenoxyethyl group incorporated into the heterocyclic 2,3-dihydro-1,4-benzodioxin or 1,3-benzodioxol ring have been synthesized. Among these compounds, the benzodioxol derivative (I e) has been found to possess hypotensive activity in rats in the same range as isoxsuprine, with no alpha-adrenolytic and central sedative properties. Cardiovascular studies in dogs have shown that (I e) is less potent than isoxsuprine, although its activity is longer-lasting at an equally hypotensive dose.
Asunto(s)
Antihipertensivos/síntesis química , Isoxsuprina/análogos & derivados , Animales , Presión Sanguínea/efectos de los fármacos , Fenómenos Químicos , Química , Perros , Femenino , Hemodinámica/efectos de los fármacos , Isoxsuprina/síntesis química , Isoxsuprina/farmacología , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Norepinefrina/antagonistas & inhibidores , Ratas , Ratas EndogámicasRESUMEN
The synthesis and some pharmacological properties of five 2,3-dihydro-3-phenyl-1,4-behzodioxin derivatives (II d-h) are reported. The new compounds generally result more active as local anaesthetics, but less effective as anti-arrhythmic agents than the corresponding 1,3-benzodioxole derivatives.
Asunto(s)
Anestésicos Locales/síntesis química , Antiarrítmicos/síntesis química , Dioxinas/síntesis química , Animales , Dioxinas/farmacología , RatonesRESUMEN
A series of omega-amino-2-hydroxy-p-fluorobutyrophenones have been synthesized to evaluate the influence exerted by a hydroxyl group in alpha-position to the carbonyl on the persistence of their neuroleptic and collateral properties. The new compounds generally did not show any neuroleptic activity while some of them were still hypotensive; this last effect, however, did not seem to be related to their alpha-adrenolytic properties.
Asunto(s)
Antipsicóticos/síntesis química , Animales , Antipsicóticos/toxicidad , Presión Sanguínea/efectos de los fármacos , Butirofenonas , Catalepsia/inducido químicamente , Fenómenos Químicos , Química , Interacciones Farmacológicas , Femenino , Humanos , Dosificación Letal Mediana , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Norepinefrina/toxicidad , Ratas , Conducta Estereotipada/efectos de los fármacosRESUMEN
Seven 1,3-benzodioxole derivatives have been found to be effective against certain types of experimentally induced arrhythmias. Among them, 2-[2-(5-chloro-2-methyl-1, 3-benzodioxol-2-yl)ethoxy]-N, N-diethyl-ethanamine (LR 529) showed to be the most active. LR 529 prevented arrhythmias induced by CaCl2 intoxication in anaesthetized and conscious rats, by benzene-epinephrine in anaesthetized guinea-pigs, and by direct electrical stimulation either at increasing intensity of the ventricles of anaesthetized cats or at increasing frequency of the rabbit isolated atria. The new compound reversed to sinus rhythm the arrhythmias provoked by intoxication with aconitine and ouabain respectively in anaesthetized rats and dogs. LR 529 (and the other 1,3-benzodioxoles as well) showed scant local anaesthetic activity, short-lasting hypotensive effects, not accompanied by any change in heart rate, and discrete anti-aggregating activity on rabbit platelets "in vitro". In general, the new compounds showed weak or no effect on autonomic and central nervous systems, neither influenced other pharmacological parameters (at least within the range of doses active on experimental arrhythmias). Acute toxicity studies have indicated that even if some of the 1,3-benzodioxoles were more toxic than quinidine and procainamide, their anti-arrhythmic indexes (especially those of LR 529) were greater than those of the two reference drugs.